News | July 30, 2025
Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Revenue increased 11.4 per cent to Rs. 8,545 crore
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Subscribe To Our Newsletter & Stay Updated
